Research and Markets: Metastatic Pancreatic Cancer - Pipeline Review, Q3 2011

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5c087f/metastatic_pancrea) has announced the addition of Global Markets Direct's new report "Metastatic Pancreatic Cancer - Pipeline Review, Q3 2011" to their offering.

“Metastatic Pancreatic Cancer - Pipeline Review, Q3 2011”

The 'Metastatic Pancreatic Cancer - Pipeline Review, Q3 2011', provides an overview of the Metastatic Pancreatic Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects.

It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer. 'Metastatic Pancreatic Cancer - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope:

• A snapshot of the global therapeutic scenario for Metastatic Pancreatic Cancer.
• A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of therapeutic class, route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy:

• Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Metastatic Pancreatic Cancer therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Key Topics Covered:

• List of Tables
• List of Figures
• Introduction
• Metastatic Pancreatic Cancer Overview
• Therapeutics Development
• - Metastatic Pancreatic Cancer Therapeutics under Development by Companies
• - Metastatic Pancreatic Cancer Therapeutics under Investigation by Universities/Institutes
• Late Stage Products
• Mid Clinical Stage Products
• Early Clinical Stage Products
• - Metastatic Pancreatic Cancer Therapeutics - Products under Development by Companies
• - Metastatic Pancreatic Cancer Therapeutics - Products under Investigation by Universities/Institutes
• - Companies Involved in Metastatic Pancreatic Cancer Therapeutics Development
• - Metastatic Pancreatic Cancer - Therapeutics Assessment
• Drug Profiles
• - Metastatic Pancreatic Cancer Therapeutics - Drug Profile Updates
• - Metastatic Pancreatic Cancer Therapeutics - Discontinued Products

For more information visit http://www.researchandmarkets.com/research/5c087f/metastatic_pancrea